Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-02-26

FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

The FDA approved Teva's supplemental application for the generic olanzapine/fluoxetine combination, expanding access to this treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Olanzapine and fluoxetine (olanzapine; fluoxetine)

Snippet

SUPPL AP for OLANZAPINE AND FLUOXETINE (OLANZAPINE AND FLUOXETINE)